

CURRICULUM VITAE

NAME: Vakaramoko (Karam), **Diaby**

HOME ADDRESS: 3550 Esplanade Way # 8208, Tallahassee, Florida, 32311

Personal e-mail: diaby_v@yahoo.fr

Tel: 850-300-9017

BUSINESS ADDRESS: 1520 S. MLK, Jr. Blvd. Dyson Building, Room 200G, Tallahassee, Florida, 32307

E-mail: vakaramoko.diaby@fam.u.edu

Tel: (850) 412-5712

Fax: (850) 412-7548

CURRENT STATUS:

Assistant Professor of Pharmaceutical Sciences, Florida A&M University, Tallahassee, Florida (Effective September 12, 2013)

EDUCATIONAL BACKGROUND:

i) Degrees:

2011 Ph.D. Pharmaceutical Sciences, Major: Drug and Population Health, Faculty of Pharmacy, University of Montreal (Quebec, Canada)

2006 M.Sc. Pharmaceutical Sciences, Major: Drug and Population Health, Faculty of Pharmacy, University of Montreal (Quebec, Canada)

2004 Clinical Research Associate Certification (CCRA), Sup Santé – Paris (France)

2003 Bachelor Biomedical Sciences, Major: Medical analyses, Faculty of Science and Technology, Hassan II Mohammedia University (Morocco)

ii) Continuing Education:

2016: Online Course - Econometrics: Theory and Application (Coursera - Erasmus University, Rotterdam, Netherlands)

2015: Workshop: Multi-Criteria Decision Analysis for Healthcare (Springer Book writing meeting - Amsterdam, Netherlands)

2014 36th Annual meeting of the society for Medical Decision Making, Miami, FL, US

2014 International Society for Pharmacoeconomics and Outcome Research (ISPOR) 19th Annual International Meeting -Montreal, QC, Canada

2013 35th Annual meeting of the society for Medical Decision Making, Baltimore, MD, US

2013 11th McMaster Clinical Epidemiology & Biostatistics research day, Hamilton, ON, Canada

2012 Online Training: Multi-Criteria Decision Analysis - Elementary and advanced methods (VRTUOSI: www.vrtuosi.com/)

2012 Workshop: Advanced decision modeling for health economic evaluation (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting -Washington, DC, USA)

2012 Workshop: Introduction to decision modeling for health economic evaluation (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting - Washington, DC, USA)

2012 Workshop: Conjoint Analysis Theory (International Society for Pharmacoeconomics and Outcome Research 17th Annual International Meeting -Washington, DC, USA)

2012 Workshop: Advanced pharmacoeconomics (Canadian Association for Population Therapeutics Annual Conference – Montreal, QC, Canada)

2012 Workshop: Introduction to pharmacoepidemiology (Canadian Association for Population Therapeutics Annual Conference – Montreal, QC, Canada)

2012 McMaster Clinical Epidemiology & Biostatistics research day, Hamilton, ON, Canada

2012 Seminar: Intravenous Thrombolysis vs. Best Medical Treatment for Late-Presentation Acute Ischemic Stroke - An Economic Evaluation in a Canadian Setting; Hamilton, ON, Canada

2011 Seminar: Oncotyrol the centre for personalized cancer research – Current research

2011 Seminar: Using Reference Manager 12 (RM12) tool in a networked environment

2011 Workshop: Health Technology Assessment: From Theory to Evidence to Policy (Programs for Assessment of Technology in Health Research Institute)

2011 Health Technology Assessment: From Theory to Evidence to Policy, Toronto, On, Canada

2004-2011 Seminars in Pharmaceutical Sciences (Attendance to over 40)

EMPLOYMENT HISTORY:

i) Academic:

09/2013 Florida A&M University, Tallahassee, Florida
Assistant professor of Pharmaceutical Sciences (Pharmacoeconomics and outcomes research)

- Teaching and Research Areas of interest:
 - ✓ *Research methods*
 - ✓ *Economic evaluation of health technologies*
 - ✓ *Pharmacoeconomics/Pharmacoepidemiology*
 - ✓ *Comparative effectiveness research*
 - ✓ *Multi-Criteria Decision Analysis for health care decision-making*

- 2013** McMaster University, Hamilton (Ontario, Canada)/PATH Research Institute
Sessional lecturer (with Professor Jean-Eric Tarride) - HRM 740: Advanced Decision Analysis in Health Technology Assessment (Health Technology Assessment)
- 2012** McMaster University, Hamilton (Ontario, Canada) Hamilton (Ontario, Canada)/PATH Research Institute
Sessional lecturer (with Professor Jean-Eric Tarride) - HRM 740: Advanced Decision Analysis in Health Technology Assessment
- 2008–2009** (6 months) Graduate Research Assistant, University of Montreal, Ste Justine Hospital of Montreal, Quebec, Canada

ii) Consultations (Biotech industry):

2004 Clinical Research Associate (CRA), RMF DICTAGENE SA, Lausanne – Vaud-Switzerland

SCHOLARLY AND PROFESSIONAL ACTIVITIES:

i) Membership to Editorial Boards

1. Editorial board member, *Pharmacoeconomics – Open* (Effective September 2016)

ii) Peer-Review Journal Referee

2016 Referee for several peer-reviewed journals including JAMA Oncology, BMC Cancer, Breast Cancer Research and Treatment, Pharmacoeconomics, Applied health Economics and Health Policy, Value in Health, Expert Review of Pharmacoeconomics and Outcomes research, Inderscience

2015 Referee for BMC Health Services Research, Breast Cancer Research and Treatment, Pharmacoeconomics, Applied health Economics and Health Policy, Expert Opinion On Pharmacotherapy, ISPOR MCDA Task Force, ISPOR–North America

2014 Referee for Patient: Patient centered outcomes research, Medical Decision Making, Cost-effectiveness and Resource Allocation, Annals of Internal Medicine, Health Services Insights, BMC Health Services Research, Systematic Reviews, The Breast, Pharmacoeconomics and Quality of Life Research, ISPOR–Europe

2013 Referee for European Journal of Health Economics, Operations Research in Health Care, Dove medical press, Patient: Patient centered outcomes research, International Society for Pharmacoeconomics and Outcomes Research (ISPOR)–Europe

2012 Pharmacy Practice

iii) Membership to Professional Societies and Certifications

1. Member, International Society of Pharmacoeconomics and Outcomes Research (ISPOR)
2. Member, Society for Medical Decision Making (SMDM)
3. Certified Clinical Research Associate (CCRA)
4. Member, American Association of Colleges of Pharmacy (AACP)

HONOURS & FELLOWSHIPS:

2016 Highly Cited Research in Operations Research For Healthcare
2016 Teacher of the Year 2015, Florida A&M University
2015: Interview with the Globe and Mail about research in geriatric pharmacoeconomics
2015 Teacher of the Year 2014, Florida A&M University
2015 Elsevier Reviewer Recognition
2013 Abstract selection for the Presidential Poster Section by the American Geriatrics Association
2012 Mitacs Accelerate Award
2012 Bernie O'Brien Post-Doctoral Fellowship Award
2011 Recommendation to the Dean's Honour List for Doctoral Thesis
2011 Pfizer Postdoctoral Fellowship in Health Economics
2006 Canadian Association for Population Therapeutics (CAPT) Studentship Award

OTHER EDUCATIONAL CONTRIBUTIONS

i) Undergraduate:

2009 Introduction to Pharmacoeconomics, tutor, 1 term, Faculty of Pharmacy, University of Montreal 16 h

TOTAL EDUCATION HOURS:

2009 Introduction to Pharmacoeconomics, tutor, 1 term, Faculty of Pharmacy, University of Montreal 16 h

RESEARCH FUNDING (GRANTS):

i) Funded Peer-Reviewed agencies, Local and Federal Government bodies

1. **National Institute on Minority Health and Health Disparities (NIMHD)-National Institutes of Health (NIH)-Research Centers in Minority Institutions (RCMI).** Assessing the benefits of cancer treatments using quality adjusted progression free survival. **Vakaramoko Diaby (PI).** May 18, 2015 – March 31, 2016 (\$20,000)
2. **Canadian Institute of Health Research.** Improving patient-reported outcome measures to support evidence based decision-making: establishing measurement properties of the EQ-

5D.

Feng Xie (Principal investigator), Eleanor Pullenayegum; Daria O'Reilly, Jean-Eric Tarride, Ron Goeree (**co-investigators**); **Vakaramoko Diaby (Canadian Institute of Health Research team member)**; February 1, 2012 – January 31, 2014 (\$198,435)

3. Mitacs Accelerate Grant. Multi-Criteria Decision Analysis (MCDA) as an Alternative Decision Making Framework for Health Technology Assessment
Vakaramoko Diaby (PI), Ron Goeree (co-investigator)
December 1, 2012 – August 31, 2013 (\$30,000).

ii) Funded University and Private sector grants

1. Canadian cost-effectiveness analysis of tofacitinib for the treatment of rheumatoid arthritis
Jean-Eric Tarride (Principal Investigator); Gord Blackhouse, Natasha Burke, Kaitryn Campbell, **Vakaramoko Diaby**, Na Guo, Ron Goeree (**Co-investigators**)
Pfizer Canada Inc. April 2012 – September 2012 (\$50,400)
2. Bernie O'Brien Professional development Grant
November 26, 2012 – November 25, 2014 (\$ 5,000)
Vakaramoko Diaby (PI)

iii) Funded Post-Doctoral Fellowships

1. Pfizer Postdoctoral Fellowship in Health Economics
October 2011 – September 2012, (\$ 85,000)
2. **Amgen Postdoctoral Fellowship** in Health Economics/Multi-criteria Decision Analysis
October 2012 – September 2013, (\$ 60,000)

iv) Submitted Federal Grant applications

1. Racial disparity in men preferences and trade-offs for prostate cancer screening in Florida: A Discrete Choice Experiment
Askal A. Ali (PI), **Vakaramoko Diaby (Co-investigator)**. Submitted (2016) to **the National Institute on Minority Health and Health Disparities (NIMHD)-National Institutes of Health (NIH)-Research Centers in Minority Institutions (RCMI)**.
2. **Health Services Research Projects (R01)**. Bridging Ethnic and Racial Disparity in Ischemic Heart Disease Health Outcomes.
Arinze Okere (PI); **Vakaramoko Diaby**; Askal Ali; Sandra Suther; Otis Kirksey; Sandra Suther; Lillian Smith; Edna Knight (**Co-investigators**) Submitted (2016) to the **Agency for**

Healthcare Research & Quality (AHRQ)

3. **Research Initiative for Scientific Enhancement (RISE) R25.** Supporting educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce with a primary focus on providing research experiences and courses for skills development.
Seth Ablordeppey (PI), **Vakaramoko Diaby (Research mentor)**. Submitted (2016) to the **National Institutes of Health (NIH)**.
4. Early HIV Treatment to Optimize Patient Health and HIV Prevention (U18). Michael Thompson (PI), Vakaramoko Diaby (**Pharmacoeconomist**). Submitted (2015) to the **Centers for Disease Control and Prevention**.

v) To be submitted-Federal Grant applications

1. Health Services Research (R01). Comparative effectiveness of Trastuzumab-based regimens for early-stage HER-2 positive breast cancer in the elderly and minority patients.
Vakaramoko Diaby (PI), Askal A. Ali (Co-PI), Hong Xiao, Alberto Montero, Joel Hay (Co-investigators). To be submitted (January 2017) to the **National Cancer Institute (NCI)**.
2. NSF 15-504 – Major Instrumentation Research Program. ELECTRE 1 Software development to support clinical and formulary decision-making in oncology.
Vakaramoko Diaby (PI), Hongmei Chi (Co-PI), Sandra Suther, Askal Ali, Bernadette Leger Guirand (Co-investigators). To be submitted (January 2017) to the **National Science Foundation**.

vi) Unfunded Research Grant applications

1. Using quality adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized controlled trials: Case of the BOLERO-2 trial.
Vakaramoko Diaby (PI). Submitted (2013) to **Faculty Research Awards Program (FRAP)**.
2. Advancing the treatment of metastatic breast cancer (mBC) through implementation of new clinical paradigms.
Alberto Montero (PI), **Vakaramoko Diaby (Co-investigator)**, Georges Adunlin (Co-investigator). Submitted (2013) to the **Avon Foundation Breast cancer Research Program**.
3. Converting health related quality of life data from BOLERO-2 trial into health Utilities.
Vakaramoko Diaby (PI). Submitted (2014) to the **American Association of Colleges of Pharmacy (AACP)-New Investigators Program**.

4. **NIMHD** Transdisciplinary Collaborative Centers for Health Disparities Research on Chronic Disease Prevention (U54). Cynthia Harris (PI), **Vakaramoko Diaby (Methodologist)**. Submitted (2015) to the **National Institutes of Health (NIH)**.
5. **Canadian Institute of Health Research**. Can healthcare reimbursement decision-making for drug and non-drug therapies be improved through use of multicriteria decision analysis? Cara Tannembaum (PI), Ron Goeree, **Vakaramoko Diaby**, Reiner Banken, André Guérard (**co-investigators**). Submitted (2014) to the **Canadian Institute of Health Research**.

FILED PATENT APPLICATIONS

ELECTRE 1 software for operations research for healthcare (**Provisional patent filed**).

LIFETIME PUBLICATIONS: (A star indicates senior author*; Underlining is meant for publications while in Assistant Professor Rank (see below))

i) PEER-REVIEWED:

a) Journal Articles:

1. Askal Ayalew Ali, Hong Xiao, Rima Tawk, Ellen Campbell, Anastasia Semykina, Alberto J Montero, **Vakaramoko Diaby***. Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. *Current medical research and opinion*. <http://dx.doi.org/10.1080/03007995.2016.1257983>
2. Boulin M, **Diaby V***, Tannembaum C. (2016). Preventing unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada. *PloS one* 11.9 (2016): e0162951.
3. **Diaby V**, Adunlin G, Ali A, Lopes G, Zeichner S, Kohn C, Montero A. (2016). Cost-effectiveness of treatment sequencing for metastatic HER2-positive breast cancer patients. *Breast Cancer Research and Treatment*. 160.1: 187-196.
4. **Diaby, V.**, Ali, A. A., Adunlin, G., Kohn, C. G., & Montero, A. J. (2016). Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. *Current medical research and opinion*, 1-6.

5. Askal Ayalew Ali, Hong Xiao, Ellen S. Campbell, **Vakaramoko Diaby***. (2016). Improving Health Care Decision Making in the USA Through Comparative Effectiveness Research: The Role of Economic Evaluation. *Pharm Med*. DOI 10.1007/s40290-015-0113-7
6. **Vakaramoko Diaby**, Vassiki Sanogo, Kouame Richard Moussa. (2016). ELICIT: An alternative imprecise weight elicitation technique for use in multi-criteria decision analysis for healthcare. *Expert review of pharmacoeconomics & outcomes research*. DOI:10.1586/14737167.2015.1083863
7. Tannenbaum, C., **Diaby, V.**, Singh, D., Perreault, S., Luc, M., & Vasiliadis, H. M. (2015). Sedative-hypnotic medicines and falls in community-dwelling older adults: a cost-effectiveness (decision-tree) analysis from a US Medicare perspective. *Drugs & aging*, 32(4), 305-314.
8. **Diaby, V.**, Tawk, R., Sanogo, V., Xiao, H., & Montero, A. J. (2015). A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. *Breast cancer research and treatment*, 151(1), 27-40.
9. Adunlin, Georges, **Vakaramoko Diaby***, and Hong Xiao. "Application of multicriteria decision analysis in health care: a systematic review and bibliometric analysis." *Health Expectations* (2014).
10. **Diaby, V.**, Goeree R, Hoch, J., Siebert, U. Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Canada: Insights from an expert panel discussion *Expert review of pharmacoeconomics & outcomes research* 15.1 (2014): 13-19
11. **Diaby, V.**, Adunlin, G., Ali, A. A., & Tawk, R. (2014). Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. *Breast cancer research and treatment*, 146(3), 669-673.
12. **Diaby, V.**, Adunlin, G., Zeichner, S. B., Avancha, K., Lopes, G., Gluck, S., & Montero, A. J. (2014). Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. *Breast cancer research and treatment*, 1-9.
13. **Diaby, V.**, Adunlin, G., & Montero, A. J. (2014). Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial. *Pharmacoeconomics*, 32(2), 101-108.
14. Adunlin, G., **Diaby, V***, Montero, A. J., & Xiao, H. (2014). Multicriteria decision analysis in oncology. *Health Expect*. 2014 Mar 17. doi: 10.1111/hex.12178. [Epub ahead of print].

15. **Diaby, V.**, & Goeree, R. (2014). How to use multi-criteria decision analysis methods for reimbursement decision-making in healthcare: a step-by-step guide. *Expert review of pharmacoeconomics & outcomes research*, 14(1), 81-99.
16. Goeree, R., & **Diaby, V***. (2013). Introduction to health economics and decision-making: Is economics relevant for the frontline clinician? *Best Practice & Research Clinical Gastroenterology*, 27(6), 831-844.
17. Tanios N, Wagner M, Tony M, Baltussen R, van Til J, Rindress D, Kind P, Goetghebeur MM, **International Task Force on Decision Criteria** (including: Ferraz MB, Carrasqueiro S, Chinitz D, Chitama D, Clifford T, Cumming J, **Diaby V**, Flamion B, Gerber-Grote A, Goeree R, Guindo A, Harstall C, Jacobs P, Jehu-Appiah C, Kletchko S, Lettieri E, Longworth L, Martin J, McDonald K, Miot J, Niessen L, Paolucci F, Peacock S, Poulin P, Raisch DW, Rajasekaran S, Ryan F, Siebert U, Tringali M, Waldau S, Wong P). Which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers [In Press]. *Int J Technol Assess Health Care* 2013.
18. Adunlin, G., Xiao, H., & **Diaby, V***. (2013). Exploring the state of pharmacy profession: The perspective of Côte d'Ivoire. *Currents in Pharmacy Teaching and Learning*, 5(5), 470-476.
19. **Diaby, V.**, Campbell, K., & Goeree, R. (2013). Multi-criteria decision analysis (MCDA) in health care: a bibliometric analysis. *Operations Research for Health Care*, 2(1), 20-24.
20. **Diaby, V.**, & Lachaine, J. (2011). An application of a proposed framework for formulary listing in low-income countries. *Applied health economics and health policy*, 9(6), 389-402.
21. **Diaby, V.**, Kakou, H. D., & Lachaine, J. (2011). Eliciting preferences for reimbursed drugs selection criteria in Côte d'Ivoire. *The Patient: Patient-Centered Outcomes Research*, 4(2), 125-131.
22. **Diaby, V.**, Laurier, C., & Lachaine, J. (2011). A proposed framework for formulary listing in low-income countries. *Pharmaceutical Medicine*, 25(2), 71-82.
23. **Diaby V**, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. *Maturitas*. 2007 Oct 20;58(2):138-49. Epub 2007 Sep 17.

b) Letters to the Editor

1. **Diaby, V.**, Adunlin, G., & Montero, A. J. (2013). Re: Xie, J, Diener M, De G et al. Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United

States. *Journal of Medical Economics*. 2013; 16 (2): 278–288. *Journal of medical economics*, 16(2).

c) Errata

1. **Diaby, V.**, Kakou, H. D., & Lachaine, J. (2011). Erratum to: Eliciting Preferences for Reimbursed Drugs Selection Criteria in Côte d'Ivoire. *The Patient: Patient-Centered Outcomes Research*, 4(2), 132-132.
2. **Diaby, V.**, Adunlin, G., Zeichner, S. B., Avancha, K., Lopes, G., Gluck, S., & Montero, A. J. (2014). Erratum to: Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. *Breast cancer research and treatment*, 147(2), 443-443.

d) Accepted and published book chapters

1. **Diaby V.**, Goeree R. Coverage with evidence development in comparative effectiveness research: In Sobolev B. (Ed.) *Handbook of Health Services Research: Springer Reference* (www.springerreference.com). Springer-Verlag Berlin Heidelberg. DOI: 10.1007/SpringerReference_303330 2012-09-25 14:01:47 UTC.
2. **Diaby V.**, Dias L. Beyond Value Function Methods in Multi-Criteria Decision Analysis for Healthcare (*Commissioned by Springer- Submitted*). *Accepted*.

f) Podium presentations

1. **Diaby V** (June, 2015). Beyond value function methods in Multi-Criteria Decision Analysis for Healthcare? **Invited presentation** – *IGH-CIHR National Stakeholders' meeting to reduce over-prescription of drugs to seniors, Women's College Hospital, Toronto, January 23rd, 2015*.
2. **Diaby V** (January, 2015). Reducing over-prescription of drugs to seniors: The question isn't whether to do it – It's How to do it? **Invited presentation** – *IGH-CIHR National Stakeholders' meeting to reduce over-prescription of drugs to seniors, Women's College Hospital, Toronto, January 23rd, 2015*.
3. **Diaby, V.** (2014, October). Cost-effectiveness analysis of metastatic breast cancer treatments: A study based on the bolero-2 trial. In *The 36th Annual Meeting of the Society for Medical Decision Making. SMDM*.

4. **Diaby V.** Current state of research on alternative decision-making framework for HTA. **Invited presentation** – *CADTH Symposium, Delta St John's, Newfoundland, May 5, 2013.*
5. **Diaby V.** Multi criteria decision analysis, a framework for drug reimbursement decision making. **Guest speaker** - *Pfizer educational rounds, Pfizer Head Office, Montreal, QC, April 16, 2013.*
6. **Diaby V.** Methods for the development of formularies in developing countries. **Invited presentations** - *Mutuelle des Fonctionnaires et Agents de l'Etat de Côte d'Ivoire, Abidjan, Côte d'Ivoire, September 17 – November 05 2012.*
7. **Diaby V.** Potential Strengths and Limitations of Multi-Criteria Decision Analysis for Use in Decision-Making Frameworks. **Invited presentation** - *Decision Determinant Committee, Health Quality Ontario, Toronto, ON, July 10, 2012.*
8. **Diaby V.** Using Multi-Criteria Decision Analysis to Inform Healthcare Decision-Making in Canada: A Post-Doctoral Fellow's Perspective. **Invited presentation** - *Pfizer Research Exchange Dinner, Westin Hotel, Ottawa, ON, April 16, 2012.*

j) Poster presentations and Published Abstracts:

1. **Diaby V,** Adunlin G, Ali A, Zeichner S, Lopes G, Kohn CG, Montero AJ. Cost Effectiveness of Different Targeted Treatment Sequences for HER2-Positive Metastatic Breast Cancer. *Value in Health.* 2016 May 1;19(3):A150.
2. Ali AA, Adunlin G, Xiao H, **Diaby V***. Reconstruction of individual patient data based on published Kaplan-Meier curves: Case of regorafenib for colorectal cancer. *Value in Health.* 2015 May 1;18(3):A19.
3. **Diaby, V.** Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial. The 19th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research. *ISPOR. Montreal, QC, May 31 – June 04, 2014*
4. **Diaby, V.** How can Multi-criteria Decision Analysis (MCDA) lend support to decision making in health technology assessment (HTA). *In The 35th Annual Meeting of the Society for Medical Decision Making. SMDM. Baltimore, MD, October 19-23, 2013*
5. **Diaby V,** Lachaine J, Die Kakou H. Eliciting Preferences for Reimbursed Drugs Selection Criteria in Côte d'Ivoire. Poster presentation at the *ISPOR 17th Annual International Meeting, Washington, DC, June 2-6, 2012.*

6. **Diaby V**, Lachaine J. An Application of a Proposed Framework for Formulary Listing in Low-Income Countries: Case of Côte d'Ivoire. Poster presentation at the *2012 CAHSPR Conference*, Montreal, Quebec, May 29-31, 2012.
7. **Diaby V**, Lachaine J. An Application of a Proposed Framework for Formulary Listing in Low-Income Countries: Case of Côte d'Ivoire. Poster presentation at the *2012 CAPT Annual Conference*, Montreal, Quebec, May 6-8, 2012.
8. **Diaby V**, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: The case of Côte d'Ivoire. Poster presentation at the ISPOR 14th European Congress, Madrid, Spain, 5-8 November 2011-*Value in Health* - (Vol. 14, Issue 7, Page A423, DOI: 10.1016/j.jval.2011.08.1043).
9. **Diaby V**, Lachaine J. An application of a proposed framework for formulary listing in low-income countries: The case of Côte d'Ivoire. 7th RQRUM annual meeting, Quebec, QC, Canada, June 1st-2 2011. (*J Popul Ther Clin Pharmacol* Vol 18(2):e275-e314; May 19, 2011).
10. **Diaby V**, Perreault S, Lachaine J. Economic impact of Tibolone compared with Continuous-Combined Hormone Replacement Therapy in the management of climacteric symptoms in postmenopausal women. *Can J Clin Pharmacol* Vol 13(1) Winter 2006: e128-e227; May 8, 2006.

REPORT ON TEACHING, MENTORSHIP AND COMMITTEE MEMBERSHIP

a) Teaching – Florida A&M University

- Fall 2013** PHA 6710: Research Methods I (3/15 Weeks)
- Spring 2014** PHA 5285: Principles of Pharmacoeconomics and Pharmacoepidemiology (7/15 weeks)
- Spring 2014** PHA 6717: Research Methods II (15/15 weeks)
- Summer 2014** PHA 6220: Economic Evaluation of Pharmaceuticals (10/15 weeks)
- Fall 2014** PHA 6292: Comparative Effectiveness Evaluation I (15/15 weeks)
- Fall 2014** PHA 6260: Advanced Studies in Pharmacoeconomics (15/15 weeks)
- Spring 2015** PHA 5285: Principles of Pharmacoeconomics & Pharmacoepidemiology (7/15 weeks)
- Spring 2015** PHA 6293: Comparative Effectiveness Evaluation II (7/15 weeks)
- Spring 2015** PHA 3002 c: IPPE II – Professional communications (6/15 weeks)
- Fall 2015** PHA 7979 : Advanced Research (15/15 weeks)
- Fall 2015** PHA 6938 : Research Seminar (15/15 weeks)
- Fall 2015** PHA 6710 : Research Methods (15/15 weeks)
- Spring 2016** PHA 5285 Principle Pharmeconomics & Pharmepidemiology (8/15 weeks)

Fall 2016 PHA 6938 Research Seminar (15/15 weeks)
Fall 2016 PHA 5212 Evidence-Based med (2/15 weeks)
Fall 2016 PHA 6710 Research Methods (15/15 weeks)
Fall 2016 PHA 7979 Advanced Research (15/15 weeks)

b) Other Teaching Experience – McMaster University, Hamilton, Ontario, Canada

Summer 2012 HRM-740: Advanced decision analysis in health technology Assessment (1/15 weeks)

Summer 2013 HRM-740: Advanced decision analysis in health technology Assessment (1/15 weeks)

c) Mentorship

Post-doctoral students – University of Montreal, Quebec, Canada

1. **Mathieu Boulin, Pharm.D** (Co-Advisor) (Completion: 2016)

Title: Prevention of unnecessary costs of drug-induced hypoglycemia in older adults with type 2 diabetes in the United States and Canada.

Doctoral Students (PhD) – Florida A&M University

1. **Cherrishe Brown - Bickerstaff, MPH, Ph.D. c** (Advisor and dissertation committee chair)
(Anticipated graduation date: Spring 2017)

Title: The cost-effectiveness of alternative iron chelating agents for the treatment of transfusional hemosiderosis in patients with sickle cell disease

2. **Askal Ayalew Ali, MA, Ph.D.** (Advisor and dissertation committee chair) (Graduation date: Spring 2016)

Title: Comparative effectiveness and cost-effectiveness of early-stage breast cancer treatments in the elderly

3. **Georges Adunlin, MA, Ph.D.** (Advisor and dissertation committee chair) (Graduation date: Spring 2015)

Title: Multi-criteria decision analysis in oncology: a decision support framework

Masters Students (MSc.) – University of Montreal, Quebec, Canada

1. Dharmender Singh, Pharm.D, MSc. (Co-Advisor) (Graduation date: Spring 2013)
2014)

Title: Accounting for falls in cost-effectiveness analyses of insomnia treatment strategies for older adults in Canada

Doctoral dissertation committee membership – Florida A&M University

1. Cherrishe Brown-Bickerstaff, MPH, Ph.D candidate
2. Gilbert Queely, MSc, Ph.D candidate
3. Carmen Lyttle - N'Guessan, MSc, Ph.D candidate
4. Kelli Ferrell, Pharm D., MSc., Ph.D candidate
5. Adaugo Eziyi, MPH, Ph.D candidate